28 May 2024
Oakley Capital Investments Limited
Oakley Capital Investments Limited1 ("OCI") is pleased to announce that Oakley Capital Fund V2 ("Fund V") has agreed to invest in ProductLife Group, a European provider of outsourced regulatory and compliance services to the global life sciences industry.
OCI's indirect contribution via Fund V is anticipated to be c.£41 million, which relates to OCI's share of Oakley's investment in ProductLife Group.
Further details on the transaction can be found in the below announcement from Oakley Capital3.
Oakley Capital invests in ProductLife Group, a leading player in regulatory and compliance services to the global life sciences industry
Oakley Capital, a leading pan-European private equity investor, is pleased to announce that Oakley Capital Fund V is investing in ProductLife Group, a European provider of outsourced development, regulatory and compliance services to the global life sciences industry.
ProductLife Group provides development, regulatory affairs, market access, pharmacovigilance, quality management and digital transformation services mainly to clients in the pharmaceuticals industry. The business has a diversified customer base with over 1,000 clients including 75% of the 50 largest global pharma companies. Under the leadership of Xavier Duburcq, ProductLife Group has grown significantly over the last four years, completing 16 add-on acquisitions and generating double-digit organic revenue growth. Today, ProductLife Group employs more than 1,600 people and operates across 150+ countries globally.
Oakley will work alongside management and the reinvesting shareholder, 21 Invest, leveraging our buy-and-build track record, supporting the business' continued international expansion and accelerating investments into AI technology to drive technology enablement of its services and operations.
Oakley Capital founder and Managing Partner Peter Dubens said:
"We're pleased to be investing in ProductLife Group. This is an attractive business in a large, non-cyclical market where increased regulation and outsourcing are driving growth. At the same time, the Group's investments in technology enablement are expected to drive competitive advantages in the coming years. We look forward to working with Xavier and his management team to take full advantage of this potential."
ProductLife Group CEO Dr. Xavier Duburcq said:
"We see tremendous opportunity to expand our business in the fragmented pharma services market both organically but also through acquisitions. Oakley has significant expertise executing buy-and-build and internationalisation strategies and we welcome the opportunity to collaborate with them on the next stage of ProductLife Group's journey."
- ends -
For further information please contact:
Oakley Capital Limited
+44 20 7766 6900
Steven Tredget
Greenbrook Communications Limited
+44 20 7952 2000
Rob White / Michael Russell
Deutsche Numis (Financial Adviser & Broker)
+44 20 7260 1000
Nathan Brown / Matt Goss
Notes:
LEI Number: 213800KW6MZUK12CQ815
1 About Oakley Capital Investments Limited ("OCI")
OCI is a Specialist Fund Segment ("SFS") traded investment vehicle that aims to provide shareholders with consistent long-term capital growth in excess of the FTSE All-Share Index by providing liquid access to private equity returns through investment in the Oakley Funds.
A video introduction to OCI is available at https://oakleycapitalinvestments.com/videos/
The contents of the OCI website are not incorporated into, and do not form part of, this announcement.
2 The Oakley Funds
Oakley Capital Private Equity II, Oakley Capital Private Equity III, Oakley Capital IV, Oakley Capital V, Oakley Capital Origin and Oakley Capital Origin II are unlisted lower-mid to mid-market private equity funds that aim to provide investors with significant long-term capital appreciation. The investment strategy of the Funds is to focus on buy-out opportunities in industries with the potential for growth, consolidation and performance improvement. The Oakley family of funds also includes Oakley PROfounders Fund III and Oakley Touring Venture Fund, which are venture capital funds focused on investments in entrepreneur-led, disruptive, technology led companies.
3 Oakley Capital, the Investment Adviser
Founded in 2002, Oakley Capital Limited has demonstrated the repeated ability to source attractive growth assets at attractive prices. To do this it relies on its sector and regional expertise, its ability to tackle transaction complexity and its deal generating entrepreneur network.
Important information
Specialist Fund Segment securities are not admitted to the Official List of the Financial Conduct Authority. Therefore, the Company has not been required to satisfy the eligibility criteria for admission to listing on the Official List and is not required to comply with the Financial Conduct Authority's Listing Rules.
The Specialist Fund Segment is intended for institutional, professional, professionally advised and knowledgeable investors who understand, or who have been advised of, the potential risk from investing in companies admitted to the Specialist Fund Segment.
This announcement may include "forward-looking statements". These forward-looking statements are statements regarding the Company's objectives, intentions, beliefs or current expectations with respect to, amongst other things, the Company's financial position, business strategy, results of operations, liquidity, prospects and growth. Forward-looking statements are subject to risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. Accordingly the Company's actual future financial results, operational performance and achievements may differ materially from those expressed in, or implied by, the statements. Given these uncertainties, prospective investors are cautioned not to place any undue reliance on such forward-looking statements, which speak only as at the date of this announcement. The Company expressly disclaims any obligation or undertaking to update or revise any forward-looking statements contained herein to reflect actual results or any change in the Company's expectations with regard to them or any change in events, conditions or circumstances on which any such statements are based unless required to do so by the Financial Services and Markets Act 2000, the Listing Rules or Prospectus Regulation Rules of the Financial Conduct Authority or other applicable laws, regulations or rules.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.